ISL1 Romotes Enzalutamide Resistance in Castration-resistant Prostate Cancer (CRPC) through Epithelial to Mesenchymal Transition (EMT)
Jae Duck Choi(Eulji University), Seong Il Seo(Samsung Medical Center)
Cited by 0
Related Papers
Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching Analysis
|Clinical Genitourinary Cancer|2017|24
ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
|Scientific Reports|2021|22
Inhibition of PREX1 Reverses Enzalutamide Resistance in Castration-Resistant Prostate Cancer
|The World Journal of Men s Health|2025|1